

## MATERIALS LICENSE

Amendment No. 42

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

OFFICIAL RECORD COPY

Licensee		In accordance with the letter dated November 13, 1996,	
1. The William W. Backus Hospital		3. License Number 06-11734-02 is amended in its entirety to read as follows:	
2. 326 Washington Street Norwich, Connecticut 06360		4. Expiration Date July 31, 2003	
		5. Docket or Reference No. 030-01287	
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 400 millicuries	
D. Palladium 103	D. Any brachytherapy source identified in 10 CFR 35.400	D. 100 millicuries	
E. Iodine 125	E. Any brachytherapy source identified in 10 CFR 35.400	E. 500 millicuries	
F. Americium 241	F. Sealed sources (Amersham Model AMC.24)	F. 15 millicuries per source and 30 millicuries total	
G. Gadolinium 153	G. Sealed sources (IPL Model 3409)	G. Not to exceed 90 millicuries per source and 176 millicuries total	
9. Authorized use			
A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.			
B. Any imaging and localization procedure approved in 10 CFR 35.200.			
C. Any radiopharmaceutical procedure approved in 10 CFR 35.300.			
D. and E. Any brachytherapy procedure approved in 10 CFR 35.400.			
F. Use as anatomical markers.			
G. One source to be used in a Picker International triple head Model Step device for patient attenuation correction during S.P.E.C.T. imaging. One source in its shipping container for source replacement.			

9706130328 961212  
PDR ADOCK 03001287  
C PDR

ML 10

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

06-11734-02

Docket or Reference Number

030-01287

Amendment No. 42

## CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 326 Washington Street, Norwich, Connecticut.
11. The Radiation Safety Officer for this license is Jeffrey C. Rudikoff, M.D.
12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

Robert S. Bell, M.D.

35.100; 35.200

Americium 241 as an anatomical marker and motion correction point source; Gadolinium 153 for patient attenuation correction during S.P.E.C.T. imaging

Howard B. Segal, M.D.

35.100; 35.200

Gadolinium 153 for patient attenuation correction during S.P.E.C.T. imaging  
Americium 241 as an anatomical marker and motion correction point source

Sa-id Esfahanian, M.D.

35.100; 35.200

Americium 241 as an anatomical marker and motion correction point source

Ben L. Sueoka, M.D.

35.100; 35.200

Americium 241 as an anatomical marker and motion correction point source

Jeffrey C. Rudikoff, M.D.

35.100; 35.200; 35.300

Gadolinium 153 for patient attenuation correction during S.P.E.C.T. imaging  
Americium 241 as an anatomical marker and motion correction point source

Kevin L. Quinn, M.D.

35.100; 35.200

Americium 241 as an anatomical marker and motion correction point source

Richard E. Peschel, M.D., Ph.D.

Palladium 103  
Iodine 125

Kenneth B. Roberts, M.D.

Palladium 103  
Iodine 125

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

06-11734-02

Docket or Reference Number

030-01287

Amendment No. 42

Gail R. Weingast, M.D.

35.100; 35.200

Iodine 131 for treatment of hyperthyroidism  
and cardiac dysfunction

Americium 241 as an anatomical marker  
and motion correction point source

Gadolinium 153 for patient attenuation  
correction during S.P.E.C.T. imaging

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated February 28, 1992
  - B. Letter dated May 27, 1993
  - C. Letter dated November 7, 1994
  - D. Letter dated February 1, 1995
  - E. Letter dated August 18, 1995
  - F. Letter dated December 15, 1995
  - G. Letter dated July 19, 1996
  - H. Letter dated August 7, 1996
  - I. Letter dated August 14, 1996
  - J. Letter dated November 13, 1996

Date DEC 12 1996

For the U.S. Nuclear Regulatory Commission

**ORIGINAL SIGNED BY:  
JO ANN V. STAMBAUGH**

By

Nuclear Materials Safety Branch  
Region I  
King of Prussia, Pennsylvania 19406

DEC 12 1996

Mr. Mark Santamaria  
Associate Administrator  
William W. Backus Hospital  
326 Washington Street  
Norwich, CT 06360

Dear Mr. Santamaria:

This refers to your license amendment request. Enclosed with this letter is the amended license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5093 or 5239, so that we can provide appropriate corrections and answers.

Thank you for your cooperation.

Sincerely,

**ORIGINAL SIGNED BY:**  
**JO ANN V. STAMBAUGH**

JoAnn V. Stambaugh  
Division of Nuclear Materials Safety

License No. 06-11734-02  
Docket No. 030-01287  
Control No. 123909

Enclosure:  
Amendment No. 42

DOCUMENT NAME: R:\WPS\MLTR\L0611734.02

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI				
NAME	Stambaugh/jvs	gjs					
DATE	12/02/96	12/3/96	12/ /96		12/ /96		12/ /96

OFFICIAL RECORD COPY

**ML 10**



The William W. Backus  
Hospital

November 13, 1996

USNRC Region I  
475 Allendale Road  
King of Prussia, PA 19406

Mr. Dave Eberhart


The William W. Backus Hospital holds USNRC Byproduct Materials License 06-11734-02. Please amend our license by adding an additional area of use of radioactive materials, an injection area for cardiac patients. A drawing of the area is attached. This area will become a part of the restricted use areas, and we will conform to the same requirements to which we have previously committed for these areas. We confirm that we will include this area in our regular area monitoring program each day of use, and will perform weekly wipe contamination surveys each week of use.

If you have any questions please contact Dr. Jeffrey Rudikoff, Radiation Safety Officer.

The amendment fee of \$440.00 is enclosed.

Sincerely yours,

Mark Santamaria  
Associate Administrator



B-2 Stress Lab #2



BETWEEN:

License Fee Management Branch, ARM  
and  
Regional Licensing Sections

(FOR LFMS USE)  
INFORMATION FROM LTS  
-----

Program Code: 02120  
Status Code: 0  
Fee Category: 7C  
Exp. Date: 20030731  
Fee Comments:  
Decom Fin Assur Req'd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: WILLIAM W. BACKUS HOSPITAL  
Received Date: 961118  
Docket No: 3001287  
Control No.: 123909  
License No.: 06-11734-02  
Action Type: Amendment

2. FEE ATTACHED

Amount: \$440.00  
Check No.: 0336525

3. COMMENTS

Signed  
Date

R. J. Brown  
11/27/96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered ☒ 1)

1. Fee Category and Amount: 7C \$440

2. Correct Fee Paid. Application may be processed for:

Amendment ☒  
Renewal ☐  
License ☐

3. OTHER

Signed  
Date

\_\_\_\_\_  
\_\_\_\_\_

Log	Dec 5
Receipt	
Check No.	336525
Amount	\$440
Fee Category	7C
Time of Fee	AM
Check No.	12/5/96
Date Completed	12/5/96
By	JB

DEC -3 PM 7:57